Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib

References

• Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356: 115–24.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584–90.
   PubMed Web of Science ®Google Scholar
• Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009;10:992–1000.
   PubMed Web of Science ®Google Scholar
• Houk BE, Bello CL, Kang D, Amantea M. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 2009;15:2497–506.
   PubMed Web of Science ®Google Scholar
• Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: Results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010;66:357–71.
   PubMed Web of Science ®Google Scholar
• Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011;103:763–73.
   PubMed Web of Science ®Google Scholar
• van der Veldt AA, Eechoute K, Gelderblom H, Gietema J, Guchelaar HJ, van Erp NP, et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 2010;17:620–9.
   PubMed Web of Science ®Google Scholar
• Garcia-Donas J, Esteban E, Leandro-García LJ, Castellano DE, Del Alba AG, Climent MA, et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: A multicentre, observational, prospective study. Lancet Oncol 2011;12:1143–50.
   PubMed Web of Science ®Google Scholar
• Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, et al. Single nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. Br J Cancer 2013;108:887–900.
   PubMed Web of Science ®Google Scholar
• Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, et al. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib – a multicentric retrospective analysis. Acta Oncol 2014;53: 103–12.
   PubMed Web of Science ®Google Scholar
• Xu CF, Bing N, Ball H, Rajagopalan D, Sternberg C, Hutson T, et al. Pazopanib efficacy in renal cell carcinoma: Evidence for predictive genetic markers in angiogenesis- related and exposure-related genes. J Clin Oncol 2011; 29:2557–64.
   PubMed Web of Science ®Google Scholar
• Xu CF, Ball HA, Bing N, Sternberg C, Xue Z, McCann L, et al. Association of genetic markers in angiogenesis- or exposure-related genes with overall survival in pazopanib-treated patients with advanced renal cell carcinoma. J Clin Oncol 2011;29(Suppl 7):abstr 303.
   Web of Science ®Google Scholar
• Reumers J, De Rijk P, Zhao H, Liekens A, Smeets D, Cleary J, et al. Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing. J Nat Biotechnol 2011;30:61–8.
   PubMed Web of Science ®Google Scholar
• Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. J Clin Oncol 2009;27:5794–9.
   PubMed Web of Science ®Google Scholar
• Dietrich CG, Geier A, Oude Elferink RPJ. ABC of oral bioavailability: Transporters as gatekeepers in the gut. Gut 2003;52:1788–95.
   PubMed Web of Science ®Google Scholar
• Walsh N, Larkin A, Kennedy S, Connolly L, Ballot J, Ooi W, et al. Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. BMC Urol 2009;9:6.
   PubMedGoogle Scholar
• Soto-Vega E, Arroyo C, Richaud-Patin Y, Garcia-Carrasco M, Vazquez-Lavista LG, Llorente L. P-glycoprotein activity in renal clear cell carcinoma. Urol Oncol 2009;27: 363–6.
   PubMed Web of Science ®Google Scholar
• Diekstra MH, Klümpen HJ, Lolkema MP, Yu H, Kloth JS, Gelderblom H, et al. Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662. Clin Pharmacol Ther 2014 Feb 24; doi: 10.1038/clpt.2014.47. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Sakamoto KM. Su-11248 Sugen. Curr Opin Invest Drugs 2004;5:1329–39.
   PubMedGoogle Scholar
• Tirona RG, Lee W, Leake BF, Lan LB, Cline CB, Lamba V, et al. The orphan nuclear receptor HNF4[alpha] determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 2003;9:220–4.
   PubMed Web of Science ®Google Scholar
• Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: A key regulator of xenobiotic metabolism. Endocr Rev 2002;23:687–702.
   PubMed Web of Science ®Google Scholar
• Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27: 1280–9.
   PubMed Web of Science ®Google Scholar